Clinical trials: Disorder, Mood
Major Depressive Disorder
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life, and effect, if any, on…
- Trial name
- AMETHYST (NCT00278941)
- Testing
- Quetiapine Fumarate Sustained Release
- Where
- 168 sites in United States, Bulgaria and 6 more
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Dysmenorrhea, Headache, Migraine
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
- Conditions
- Dysmenorrhea, Headache, Migraine, Fatigue, Nausea
- Trial name
- NCT04091789
- Testing
- Pure Femme Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Bipolar Disorder
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine.
- Trial name
- NCT00360126
- Testing
- lamotrigine
- Where
- 3 sites in Australia
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Treatment Resistant Depression
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
- Trial name
- NCT05624268
- Testing
- Psilocybin
- Where
- 40 sites in United States
- Volunteers
- 258 people
- Sponsor
- COMPASS Pathways
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder
Real-life Effectiveness of Vortioxetine in Depression
Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences. Vortioxetine (Brintellix®) is a new antidepressant authorized since 2013.
- Trial name
- RELIEVE (NCT03555136)
- Testing
- Vortioxetine
- Where
- 106 sites in United States, Canada and 2 more
- Volunteers
- 992 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale…
- Trial name
- NCT02948036
- Testing
- Mobile-device, plasticity-based adaptive cognitive treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Memory Dysfunction, Mood Disorders
To Access the Effect of Brain Pill™ on Working Memory Capacity and Mood Behaviour.
Brain Pill™ is a mental health enhancing and successfully marketed dietary supplement.
- Trial name
- NCT03198936
- Testing
- Cognizin® SynapsaTM
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Bipolar Disorder
Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients
The purpose of this study is to determine whether the sedating (causing sleepiness) effects of risperidone or quetiapine alter cognitive (person's ability to think, perceive, recognize, remember, judge, and reason) functioning in…
- Trial name
- NCT00097032
- Testing
- risperidone; quetiapine
- Volunteers
- 30 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder.
- Trial name
- NCT00107926
- Testing
- Licarbazepine
- Where
- 44 sites in United States, Austria and 11 more
- Volunteers
- 343 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
On 6 Feb 2014, Pristiq was approved for the treatment of Major Depressive Disorder(MDD) in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS for 600 patients by 5 Feb 2020.
- Trial name
- PMS (NCT02548949)
- Where
- 22 sites in South Korea
- Volunteers
- 700 people
- Sponsor
- Pfizer
Depressive Disorder, Major
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.
- Trial name
- NCT01870843
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 261 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus SSRI
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- EMBOLDEN II (NCT00119652)
- Testing
- quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 676 people
- Sponsor
- AstraZeneca
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.